Collaborative Network to Take Responsibility for Oral Anticancer Therapy (CONTACT)
CONTACT: A Prospective Interventional Multicentre Before-after Study for the Implementation of a Care Pathway to Increase Self-management of Patients With Cancer Who Are Treated With Oral Anticancer Medications
This study aims to develop, implement and evaluate a care pathway for patients with cancer who are treated with oral anticancer drugs (OACD).
The care pathway will be developed in six hospitals in Flanders, and will be adapted to the local setting and situation.
The investigators hypothesize that the implementation of a care pathway will increase the quality of the drug therapy, the communication between health care professionals (HCPs) and patients, and will lead to an improved level of self-management and adherence. Moreover, the invesitgators hypothesize that the care pathway will facilitate the communication between HCPs in the hospital setting and in ambulatory care, and will improve counseling skills, self-efficacy and self-confidence of HCPs.
At the end of the study, a roadmap for the nation-wide implementation of a similar care pathway will be constructed based on the experiences of the participating hospitals. This roadmap will certainly include an e-learning platform for healthcare professionals.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
For each hospital, an individual care pathway will be developed following the 7-phase model by Vanhaecht et al., 2011. This methodology aims to offer a systematic approach in 7 phases for the support of an interdisciplinary team in the development of new care pathways or in the improvement of existing ones.
The before-part of the study includes phases 1 to 4 that aim to map current practice in detail and to translate these findings into the development of a care pathway. Current practice will be investigated using mixed methods comprising:
- surveys evaluating care on the level of the hospital
- semi-structured interviews with healthcare professionals (HCP) and patients
- outcome assessments in patients included in the study (self-management, adherence, satisfaction with care, satisfaction with information, quality of life) using validated questionnaires at the start of the therapy, after 1 month and after three months
- outcome assessments in healthcare professionals at baseline (self-efficacy and perceptions on self-management) using validated questionnaires
- training and feedback sessions on counseling for HCPs
Based upon these findings, a care pathway in each hospital will be developed by a local project team of different stakeholders from different disciplines.
The after-part of the study includes phase 5-7 in which the care pathway is implemented, evaluated and continuously followed up.
Implementation and evaluation take place at the same time. The evaluation includes:
- outcome assessments in patients (newly recruited) at the start of the therapy, after 1 month and after three months
- outcome assessments in HCPs (follow up)
- evaluation of counseling skills
- focus group discussions and interviews with HCPs to evaluate the development and implementation of the care pathway.
At the end of the study a comparison of outcomes before and after the implementation will be made to study the impact of the care pathway on the before mentioned aspects (see "Brief Summary").
Тип исследования
Регистрация (Ожидаемый)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Antwerpen
-
Turnhout, Antwerpen, Бельгия, 2300
- Рекрутинг
- AZ Turnhout
-
Контакт:
- Lise-Marie Kinnaer, PharmD
- Номер телефона: 32 16328265
- Электронная почта: lisemarie.kinnaer@kuleuven.be
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Бельгия, 9000
- Рекрутинг
- Maria Middelares GENT
-
Контакт:
- Lise-Marie Kinnaer, PharmD
- Номер телефона: 32 16328265
- Электронная почта: lisemarie.kinnaer@kuleuven.be
-
-
Vlaams-Brabant
-
Bonheiden, Vlaams-Brabant, Бельгия, 2820
- Рекрутинг
- Imelda Bonheiden
-
Контакт:
- Lise-Marie Kinnaer, PharmD
- Номер телефона: 32 16328265
- Электронная почта: lisemarie.kinnaer@kuleuven.be
-
-
West-Vlaanderen
-
Kortrijk, West-Vlaanderen, Бельгия, 8000
- Рекрутинг
- AZ Groeninge Kortrijk
-
Контакт:
- Veerle Foulon, Prof. Dr.
- Электронная почта: veerle.foulon@kuleuven.be
-
Контакт:
- Lise-Marie Kinnaer, PharmD
- Номер телефона: 32 016328265
- Электронная почта: lisemarie.kinnaer@kuleuven.be
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- a hematological cancer of solid tumor
- starting an oral anticancer drug for the first time
- able to understand and speak Dutch
Exclusion Criteria:
- patients following an adjuvant oral anticancer therapy (e.g. tamoxifen)
- patients following a therapy with a study drug
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Поддерживающая терапия
- Распределение: Нерандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Без вмешательства: Non-care pathway
This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician. |
|
|
Экспериментальный: Care Pathway
This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician. |
The care pathway will consist of procedures of care in the hospital (e.g.
consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up.
The care pathway should describe how care can efficiently be organised.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in self-management skills
Временное ограничение: at the start of the therapy, after one and three months
|
There is no gold standard to define self-management. A definition from Barlow et al., 2002 (2) defines self-management as follows: the ability of an individual to manage the symptoms, treatment, physical and psychosocial consequences and life style changes due to his/her condition. Adequate self-management refers to the ability to monitor one's condition and to effect cognitive, behavioural and emotional responses necessary to maintain a satisfactory quality of life. The studied self-management skills in this project comprise "social integration and support", "health service navigation", "constructive attitudes and approaches", "skill and technique acquisition" and "emotional distress". |
at the start of the therapy, after one and three months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in medication Adherence
Временное ограничение: after one and three months of therapy
|
after one and three months of therapy
|
|
|
Change in patient satisfaction with treatment using the Cancer Therapy Satisfaction Questionnaire (CTSQ)
Временное ограничение: after one and three months
|
after one and three months
|
|
|
Change in patient satisfaction with care using Out-patsat 35
Временное ограничение: at the start of the therapy, after one and three months
|
The outpatsat is a questionnaire for ambulatory cancer patients in which they are asked to rate in different subscales their perceptions on care delivered by doctors, nurses and rate te overall organisation (accessibility of the hospital, ease of reaching the hospital by telephone, ...) during their stay at day hospital of consultations
|
at the start of the therapy, after one and three months
|
|
Health Related Quality of Life
Временное ограничение: at the start of the therapy, after one and three months
|
at the start of the therapy, after one and three months
|
|
|
Change in Distress using the Distress Barometer
Временное ограничение: at the start of the therapy, after one and three months
|
at the start of the therapy, after one and three months
|
|
|
Efficacy of treatment Using ECOG performance scale and RECIST criteria
Временное ограничение: at the start of the therapy, after one and three months
|
at the start of the therapy, after one and three months
|
|
|
Toxicity of treatment
Временное ограничение: at the start of the therapy, after one and three months
|
Summarizing adverse drug events
|
at the start of the therapy, after one and three months
|
|
Cost of care
Временное ограничение: at the start of the therapy, after one and three months
|
Prospective report on health care expenditures (use of healthcare and other services, use of medicines, …)
|
at the start of the therapy, after one and three months
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in Self-efficacy in HCPs using the Self-efficacy and Performance in Self-management Instrument (SEPSS)
Временное ограничение: at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
SEPSS investigates the ability of a HCP to evaluate their own performance in daily practice and caregiving.
|
at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
|
Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure
Временное ограничение: at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Ожидаемый)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Заболевания пищеварительной системы
- Новообразования по гистологическому типу
- Новообразования
- Новообразования по локализации
- Желудочно-кишечные новообразования
- Новообразования пищеварительной системы
- Желудочно-кишечные заболевания
- Нейроэктодермальные опухоли
- Новообразования, зародышевые клетки и эмбриональные
- Новообразования, нервная ткань
- Заболевания толстой кишки
- Кишечные заболевания
- Новообразования кишечника
- Заболевания прямой кишки
- Нейроэндокринные опухоли
- Невусы и меланомы
- Колоректальные новообразования
- Меланома
Другие идентификационные номера исследования
- LMK15022016
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .